Borosil Scientific Board Meeting Scheduled for May 20, 2026 to Approve FY26 Results and Fund-Raising Resolution
Borosil Scientific Limited has scheduled a Board of Directors meeting for May 20, 2026, to approve audited financial results for the quarter and financial year ended March 31, 2026 (Standalone & Consolidated). The board will also consider an enabling resolution for shareholders' approval to raise funds through modes including Qualified Institutional Placement, Further Public Offer, and Foreign Currency Convertible Bonds. A fresh shareholder approval is being sought as the earlier approval obtained at the AGM held on August 11, 2025, carries a validity of 365 days under certain SEBI Regulations. The Trading Window for designated persons has been closed since April 1, 2026, and will remain shut until 48 hours post the results declaration.

*this image is generated using AI for illustrative purposes only.
Borosil Scientific Limited has notified the stock exchanges of an upcoming Board of Directors meeting scheduled for Wednesday, May 20, 2026, in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation was filed on May 13, 2026, and signed by Sanjay Gupta, Company Secretary & Compliance Officer (ICSI Membership No.: A24641).
Key Agenda Items for the Board Meeting
The board meeting has been convened to address two primary matters. The following table summarises the key agenda items:
| Agenda Item: | Details |
|---|---|
| Financial Results: | Audited Financial Results (Standalone & Consolidated) for the quarter and financial year ended March 31, 2026 |
| Fund-Raising Resolution: | Enabling resolution for shareholders' approval to raise funds through various modes |
Fund-Raising Modes Under Consideration
The board will seek shareholders' approval through an enabling resolution for raising funds via multiple avenues, subject to applicable regulatory and statutory approvals. The modes being considered include:
- Qualified Institutional Placement (QIP)
- Further Public Offer (FPO)
- Issuance of Foreign Currency Convertible Bonds (FCCBs)
- Any other method or a combination thereof, as permitted under applicable laws
Context for Fresh Shareholder Approval
Borosil Scientific noted that a similar approval was obtained from shareholders at the Annual General Meeting (AGM) held on August 11, 2025. Under certain SEBI Regulations, such approval carries a validity of 365 days from the date of approval. In view of this, the company has proposed seeking a fresh approval from shareholders on similar lines at the ensuing AGM, which would provide the company the flexibility to raise funds as and when needed using the most suitable mode.
Trading Window Closure
In connection with the upcoming declaration of financial results, the Trading Window for dealing in the equity shares of the company for all Designated Persons and their immediate relatives was closed from April 1, 2026. The window will remain closed until 48 hours after the declaration of the aforesaid results, in line with applicable SEBI regulations.
The intimation has been made available on the company's website at https://www.borosilscientific.com/ .
Historical Stock Returns for BOROSCI
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.27% | -4.07% | +4.23% | -4.52% | -12.09% | -24.42% |
How might Borosil Scientific's choice between QIP, FPO, or FCCBs impact its existing shareholders' equity dilution and stock price performance post-fund raise?
What strategic expansion or capital expenditure plans could Borosil Scientific be targeting with the fresh fund-raising approval, given its position in the scientific glassware sector?
How have peer companies in the laboratory and scientific equipment space utilized similar fund-raising instruments, and what outcomes can Borosil Scientific's investors benchmark against?


































